<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Reprod Med</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Reprod Med</journal-id><journal-id journal-id-type="publisher-id">IJRM</journal-id><journal-title-group><journal-title>Iranian Journal of Reproductive Medicine</journal-title></journal-title-group><issn pub-type="ppub">1680-6433</issn><issn pub-type="epub">2008-2177</issn><publisher><publisher-name>Research and Clinical Center for Infertility</publisher-name><publisher-loc>Yazd, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26396582</article-id><article-id pub-id-type="pmc">4576434</article-id><article-id pub-id-type="publisher-id">ijrm-9-315</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Luteal phase estradiol versus luteal phase GnRH antagonist administration: their effects on antral follicular size coordination and basal hormonal levels</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rashidi</surname><given-names>Batool</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nasiri</surname><given-names>Roya</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rahmanpour</surname><given-names>Haleh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shahrokh Tehraninejad</surname><given-names>Ensieh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deldar</surname><given-names>Maryam</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Valie-Asr Reproductive Health Research Center, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="aff2"><label>2</label>Department of Obstetrics and Gynecology, Aria Hospital, Faculty of Medicine, Islamic Azad University of Medical Sciences, Mashhad Branch, Mashhad, Iran.</aff><aff id="aff3"><label>3</label>Department of Obstetrics and Gynecology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.</aff><author-notes><corresp id="cor">Corresponding Author: Haleh Rahmanpour, Department of Obstetrics and Gynecology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Email: haleh509@gmail.com</corresp></author-notes><pub-date pub-type="ppub"><season>Autumn</season><year>2011</year></pub-date><volume>9</volume><issue>4</issue><fpage>315</fpage><lpage>318</lpage><history><date date-type="received"><day>21</day><month>12</month><year>2010</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2011</year></date></history><permissions><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>The differential efficacy between long GnRH agonist with antagonist can partly be due to the preexisting differences in the early antral follicles before ovarian stimulation.</p></sec><sec><title>Objective:</title><p>To compare the effect of pretreatment by estradiol with GnRH antagonist on antral follicular size coordination and basal hormone levels in GNRH antagonist protocol.</p></sec><sec><title>Materials and Methods:</title><p>On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (<italic>n</italic>=15) or 3mg cetrorelix acetate (<italic>n</italic>=15) in luteal phase before subsequent antagonist protocol. Participants were re-evaluated as on control/day 3.</p></sec><sec><title>Results:</title><p>There was a significant reduction of mean follicular sizes in each group after medical intervention (7.63&#x000b1;2.11 Vs. 4.30&#x000b1;0.92 in group A and 8.73&#x000b1;1.96 Vs. 4.13&#x000b1;1.11 in group B) (p=0.0001). The magnitude of follicular size reduction was significantly higher in group B (-4.60&#x000b1;2.04 Vs. -3.33&#x000b1;2.28) (0.027). There was a non significant attenuation of follicular size discrepancies in two groups. FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.</p></sec><sec><title>Conclusion:</title><p>Both luteal E2 and premenstrual GnRH antagonist administration reduces the follicular sizes significantly and GnRH antagonist acts more potently than E2 in this way but attenuation of follicular size discrepancies in both treatment is not significant.</p></sec></abstract><kwd-group><title>Key Words</title><kwd><italic>Follicular synchronization</italic></kwd><kwd><italic>Estradiol</italic></kwd><kwd><italic>GnRH antagonist</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>During the early follicular phase of menstrual cycle inconsistent sensitivity of early antral follicles to FSH and their dissimilar sizes play an important role in the establishment of the follicular dominance (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). In controlled ovarian hyper stimulation (COH), asynchronous follicular growth is counterproductive and reduces the number of mature oocytes and embryos and the likelihood of conception (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Long GnRH agonist protocol is clinically applied for synchronous and coordinate growth of early antral follicles and prevention of endogenous LH surge, during COH for ART. The initial flare- up and the rather long period until pituitary suppression and hypoestrogenic side effects are the disadvantages of long GnRH agonist protocol (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B6" ref-type="bibr">6</xref>). The differential efficacy between long GnRH agonist with antagonist and short protocols can partly be due to the preexisting differences in the early antral follicles before ovarian stimulation (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Size discrepancy in early antral follicles can lead to marked follicular size discrepancies at the end of COH and smaller number of mature oocytes and embryos (<xref rid="B8" ref-type="bibr">8</xref>). It has been demonstrated that lowering endogenous gradient FSH secretion during the late luteal phase by administering either estradiol or GnRH antagonist can result in more synchronized antral follicles in the next early follicular phase (<xref rid="B9" ref-type="bibr">9</xref>) and achievement of adequate coordination of multiple follicular growths to trigger ovulation is one of the key objectives of COH (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>In the present study we wished to compare the effectiveness of late luteal phase administration of Estradiol valerate with GnRH antagonist in reducing antral follicular diameters and disparities, and FSH and inhibin B levels on day 3 of the next cycle. </p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This interventional single blind clinical trial was conducted on 30 volunteers, attending the university based infertility clinic. All the subjects were 20-35 years old women with male factor infertility and candidate for ICSI who met the following inclusion criteria: No current or past systemic disease, Regular menstrual cycles (25-35 days) and Body mass index (BMI) ranging 18-27 kg/m2. </p><p>Those with history of hormone therapy for the past preceding 3 months or single ovary were excluded. Written informed consent was obtained and the study protocol was approved by Ethics committee of Tehran University of Medical Sciences. Participants were allocated into two groups employing permuted block randomization method and followed for two consecutive menstrual cycles (60 study cycles). </p><p>On day 3 of their first menstrual cycles (baseline/day 3), transvaginal ultrasound scans of ovaries and blood sampling for serum E2, FSH, inhibin B measurement were performed. Ultrasound scans (US) were performed with a 3.5 to 5 MHZ multifrequency vaginal probe (AGUILA, Esaote, Italy) by a single operator who was not aware of the treatment schedule. In US examination the number and size of the 2-12 mm follicles (mean of two orthogonal diameters) and the diameters of ovaries were recorded. Ovarian volume was calculated as height in width in depth of the ovary multiplied by 0.526. Intra-analysis coefficients of variation (CVs) for follicular and ovarian measurements were &#x0003c;5% and their lower limit of detection were 0.1 mm. Serum FSH was determined by chemiluinescence technique (Diarson, Italy). Intra-assay and inter-assay CV were respectively 3% and 5% and lower limit detection was 0.1 mI u/ml). Serum inhibin B was determined by double-antibody ELISA (Sertec, Varilhes, France) lower limit detection was 10 Pg/ml, and intra-assay and inter assay CV were&#x0003c;6% and &#x0003c;9% respectively. Serum E2 was determined by chemiluinescence technique (Diarson, Italy). Lower limit detection was 14 Pg/ml, and intra- assay and inter assay CV were 8% and 9% respectively.</p><p>In group A (n=15), 4mg/day oral tablets of Estradiol valerate (Estradiol, Abooreihan, Iran) was administered from day 20 of the same cycle until day 2 of their next cycle for suppression of endogenous FSH secretion. Subjects in group B (n=15) received a single subcutaneous injection of 3 mg GnRH antagonist (Cetrolelix acetate, cetrotide, Serono lab, Boulogne, France) on day 25 of the same cycle. Similar US and laboratory examination were done on day 3 of their next cycles, as in their preceding cycles were performed (Estradiol/day 3 or GnRH antagonist/day 3) then these two groups enrolled the antagonist protocol.</p><p>
<bold>Statistical analysis</bold>
</p><p>Measure of central tendency used was the mean and measure of variability was standard deviation (SD) and coefficient of variation. To evaluate the magnitude of follicular size discrepancies from baseline/day 3 to E2/day 3 or GnRH antagonist/day 3, we used Fisher exact test. In addition, SD/mean ratios for follicular size were calculated. A p-value of &#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>The E2 group and the GnRH antagonist group contain 15 women in each group that were comparable with regard to age (27.1&#x000b1;3.2 Vs. 27.0&#x000b1;3.3 years), body mass index (25.4&#x000b1;1.7 Vs. 26.2&#x000b1;2.2 kg/m<sup>2</sup>) and duration of infertility (4.9&#x000b1;1.7 Vs. 5.4&#x000b1;2.4 years). Follicular and ovarian measurements and hormonal results are summarized in <xref ref-type="table" rid="T1">table I</xref>. There was a significant reduction of mean follicular sizes in each group after medical intervention (p=0.0001). The magnitude of follicular size reduction was significantly higher in group B (-4.60&#x000b1;2.04 Vs. -3.33&#x000b1;2.28) (p=0.027) (<xref ref-type="table" rid="T2">Table II</xref>). </p><p>There was a non-significant attenuation of follicular size discrepancies in E2/day3 and GnRH antagonist/day3, as shown by SD/mean ratio of follicular sizes in <xref ref-type="table" rid="T1">table I</xref>. In comparison with GnRH antagonist, E2 resulted in better follicular size homogeneity. </p><p>FSH and inhibin B levels on day 3 of the next cycle in both groups were significantly decreased but did not have difference between two groups. Serum E2 level significantly increased after treatment in group A, but did not change in group B.</p><table-wrap id="T1" position="float"><label>Table I</label><caption><p>Ultrasound and hormonal results during two consecutive menstrual cycles in women receiving E2 or GnRH antagonist in the luteal phase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" colspan="3" rowspan="1">
<bold>GnRH antagonist group (B)/Day 3</bold>
<hr/>
</th><th align="center" valign="middle" colspan="3" rowspan="1">
<bold>E2 group(A)/Day 3</bold>
<hr/>
</th><th align="justify" valign="middle" rowspan="2" colspan="1">
<bold>Parameter</bold>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>p-value</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>GnRH antagonist</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Baseline</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>p value</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>E2</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Baseline</bold>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.648<xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">9.60&#x000b1;1.57</td><td align="center" valign="middle" rowspan="1" colspan="1">9.73&#x000b1;1.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.515<xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">10.17&#x000b1;1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">10.33&#x000b1;1.35</td><td align="justify" valign="middle" rowspan="1" colspan="1">No. of follicles (range)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">4.13&#x000b1;1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">8.73&#x000b1;1.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">4.30&#x000b1;0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">7.63&#x000b1;2.11</td><td align="justify" valign="middle" rowspan="1" colspan="1">Mean follicular size (mm)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.246<xref ref-type="table-fn" rid="TFN3">***</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.869<xref ref-type="table-fn" rid="TFN3">***</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="justify" valign="middle" rowspan="1" colspan="1">SD follicular size (mm)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.206<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">9.67&#x000b1;2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">9.35&#x000b1;1.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.407<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">9.5&#x000b1;1.44</td><td align="center" valign="middle" rowspan="1" colspan="1">9.33&#x000b1;1.65</td><td align="justify" valign="middle" rowspan="1" colspan="1">Mean ovarian volume (cm3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">21.36&#x000b1;13.18</td><td align="center" valign="middle" rowspan="1" colspan="1">30.73&#x000b1;11.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">19.46&#x000b1;11.38</td><td align="center" valign="middle" rowspan="1" colspan="1">29.53&#x000b1;9.27</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum inhibin B (pg/mL)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.246<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">45.20&#x000b1;17.81</td><td align="center" valign="middle" rowspan="1" colspan="1">50.80&#x000b1;19.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">75.07&#x000b1;34.97</td><td align="center" valign="middle" rowspan="1" colspan="1">48.53&#x000b1;22.64</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum E2 (pg/mL)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">5.53&#x000b1;1.60</td><td align="center" valign="middle" rowspan="1" colspan="1">6.49&#x000b1;1.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">4.96&#x000b1;2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">5.77&#x000b1;1.83</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum FSH (mIU/mL)</td></tr></tbody></table><table-wrap-foot><p>P&#x0003c;0.05 =Significant level.</p><fn id="TFN1"><label>*</label><p>Paired samples t-test .</p></fn><fn id="TFN2"><label>**</label><p>Wilcoxon signed ranks .</p></fn><fn id="TFN3"><label>***</label><p>Levene's test for equality of variances.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table II</label><caption><p>Comparison of pre and post treatment ultrasound and hormonal result differences between group A and B.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="2" colspan="1">
<bold>p-value</bold>
</th><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>Differences between pre and post treatment cycles</bold>
<hr/>
</th><th align="justify" valign="middle" rowspan="2" colspan="1">
<bold>Parameter</bold>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>GnRH antagonist group (B)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>E</bold>
<sub>2</sub>
<bold> group (A)</bold>
</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">0.932</td><td align="center" rowspan="1" colspan="1">-0.13&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">-0.17&#x000b1;1.42</td><td align="justify" valign="middle" rowspan="1" colspan="1">No. of follicles (range)</td></tr><tr><td align="center" rowspan="1" colspan="1">0.027</td><td align="center" rowspan="1" colspan="1">-4.60&#x000b1;2.04</td><td align="center" rowspan="1" colspan="1">-3.33&#x000b1;2.28</td><td align="justify" valign="middle" rowspan="1" colspan="1">Mean follicular size (mm)</td></tr><tr><td align="center" rowspan="1" colspan="1">0.619</td><td align="center" rowspan="1" colspan="1">+0.33&#x000b1;1.39</td><td align="center" rowspan="1" colspan="1">+0.17&#x000b1;1.09</td><td align="justify" valign="middle" rowspan="1" colspan="1">Mean ovarian volume (cm3)</td></tr><tr><td align="center" rowspan="1" colspan="1">0.696</td><td align="center" rowspan="1" colspan="1">-9.37&#x000b1;4.88</td><td align="center" rowspan="1" colspan="1">-10.07&#x000b1;4.84</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum inhibin B (pg/mL)</td></tr><tr><td align="center" rowspan="1" colspan="1">0.0001</td><td align="center" rowspan="1" colspan="1">-5.60&#x000b1;17.90</td><td align="center" rowspan="1" colspan="1">+26.53&#x000b1;23.04</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum E2 (pg/mL)</td></tr><tr><td align="center" rowspan="1" colspan="1">0.720</td><td align="center" rowspan="1" colspan="1">-0.96&#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">-0.81&#x000b1;1.25</td><td align="justify" valign="middle" rowspan="1" colspan="1">Serum FSH (mIU/mL)</td></tr></tbody></table><table-wrap-foot><p>Repeated measurement analysis of variance .</p><p>P&#x0003c;0.05 =Significant level.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>This study showed that luteal FSH suppression by either E2 or GnRH antagonist administration reduces the size and improves the homogeneity of early antral follicles during the early follicular phase. These results were in accordance of Fanchines <italic>et al</italic> studies but in his studies each treatment was compared separately with no intervention (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). </p><p>Compared with GnRH agonist long protocols, the introduction of GnRH antagonist protocols for controlled ovarian hyper stimulation has offered the great opportunity to reduce the duration of treatment, the consumption of gonadotrophins and to lower the physical and psychological burden for patients submitted to pituitary desensitization (<xref rid="B11" ref-type="bibr">11</xref>). While in short GnRH agonist and GnRH antagonist regimens, the slight reduction in the number of retrieved oocytes and in the pregnancy rate reported has been partly attributed to the absence of synchronization of the follicular cohort before ovarian stimulation as compared with long GnRH agonist (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). </p><p>For that reason, more attention has been paid to the potential interest of steroid pre-treatments to program cycles, to modify the hormonal environment in relation to the negative feedback exerted by steroids on endogenous gonadotrophin secretion and therefore to synchronize the follicular cohort before stimulation. Indeed, both oral contraceptive pill (OCP), synthetic progestogens and Estradiol have been largely used for many years to program cycles (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Oral contraceptives, due to their potent anti-FSH action, may exert similar, or even stronger, coordinating effects on early follicular development compared with luteal E2 or premenstrual GnRH antagonist administration (<xref rid="B12" ref-type="bibr">12</xref>). </p><p>In recent Cochrane review it was stated, that combined OCP pre-treatment in GnRH antagonist cycles is associated with fewer clinical pregnancies and more days and a higher amount of gonadotrophin therapy and progestogen pre-treatment in GnRH agonist cycles, is associated with more clinical pregnancies and fewer ovarian cysts, at last, in estrogen pre-treated GnRH antagonist cycles, compared to no pre-treatment, more oocytes are retrieved but a higher amount of gonadotrophin therapy is needed (<xref rid="B13" ref-type="bibr">13</xref>). </p><p>In contrast, Fanchin <italic>et al</italic> showed that synchronization of the follicular cohort with estrogen pre-treatment, followed by a short wash-out period before starting stimulation, was associated with an increase in the number of follicles and oocytes retrieved (<xref rid="B14" ref-type="bibr">14</xref>). </p><p>In a recent study the addition of GnRH antagonist to luteal E2 for luteal suppression before ovarian stimulation for IVF does not improve IVF outcomes in poor responders (16). The reduction of antral follicle size discrepancy in our study was not significant and this may be due to small sample size.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, these data show both luteal E2 and premenstrual GnRH antagonist administration reduces the follicular sizes significantly but whether strong homogenization of the follicular cohort by GnRH antagonist or estrogen pre-treatment has differential effects on oocyte yield, endometrial quality and COH outcome remains to be determined in an adequately powered prospective study.</p></sec></body><back><sec><title>Note</title><p>
<bold><italic>Registration ID in IRCT: IRCT201103052568N2</italic></bold>
</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNatty</surname><given-names>KP</given-names></name><name><surname>Hillier</surname><given-names>SG</given-names></name><name><surname>Vanden</surname><given-names>Boogaard AM</given-names></name><name><surname>Trimbos-Kemper</surname><given-names>TC</given-names></name><name><surname>Reichert</surname><given-names>LE Jr</given-names></name><name><surname>van</surname><given-names>Hall EV</given-names></name></person-group><article-title>Follicular development during the luteal phase of the human menstrual cycle</article-title><source> J Clin Endocrinol Metab</source><year>1983</year><volume>56</volume><fpage>22</fpage><lpage>31</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Van</surname><given-names>Heusden AM</given-names></name></person-group><article-title>Manipulation of human ovarian function: physiological concepts and clinical consequences</article-title><source> Endocrinol Rev</source><year>1997</year><volume>18</volume><fpage>71</fpage><lpage>106</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devreker</surname><given-names>F</given-names></name><name><surname>Pogonici</surname><given-names>E</given-names></name><name><surname>De</surname><given-names>l\laertclaer V</given-names></name><name><surname>Revelard</surname><given-names>P</given-names></name><name><surname>Van</surname><given-names>den Bergh M</given-names></name><name><surname>Englert</surname><given-names>Y</given-names></name></person-group><article-title>Selection of good embryos for transfer depends on embryo cohort size: implications for the 'mild ovarian stimulation' debate</article-title><source> Hum Reprod</source><year>1999</year><volume>14</volume><fpage>3002</fpage><lpage>3008</lpage><pub-id pub-id-type="pmid">10601087</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name><name><surname>Rombauts</surname><given-names>L</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>GnRH antagonists in ovarian stimulation for IVF</article-title><source> Hum Reprod Update</source><year>2006</year><volume>12</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">16567347</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borm</surname><given-names>G</given-names></name><name><surname>Mannaerts</surname><given-names>B</given-names></name></person-group><article-title>Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial</article-title><source> The European Orgalutran Study Group. Hum Reprod</source><year>2000</year><volume>15</volume><fpage>1490</fpage><lpage>1498</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AI-Inany</surname><given-names>H</given-names></name><name><surname>Aboulghar</surname><given-names>M</given-names></name></person-group><article-title>Gonadotrophin-releasing hormone antagonists for assisted conception</article-title><source> Cochrane Database Systemic Rev</source><year>2001</year><volume>4</volume><fpage>CD001750</fpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Schonauer</surname><given-names>LM</given-names></name><name><surname>Cunha-Filho</surname><given-names>JS</given-names></name><name><surname>Lozano</surname><given-names>DHM</given-names></name><name><surname>Frydman</surname><given-names>R</given-names></name></person-group><article-title>Coordination of Antral Follicle Growth: Basis for Innovative Concepts of Controlled Ovarian Hyperstimulation</article-title><source> Semin Reprod Med J</source><year>2005</year><volume>23</volume><fpage>354</fpage><lpage>362</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Salomon</surname><given-names>L</given-names></name><name><surname>Castelo-Branco</surname><given-names>A</given-names></name><name><surname>Olivennes</surname><given-names>F</given-names></name><name><surname>Frydman</surname><given-names>N</given-names></name><name><surname>Frydman</surname><given-names>R</given-names></name></person-group><article-title>Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyper-stimulation with GnRH antagonists</article-title><source> Hum Reprod</source><year>2003</year><volume>18</volume><fpage>2698</fpage><lpage>2703</lpage><pub-id pub-id-type="pmid">14645194</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Branco</surname><given-names>AC</given-names></name><name><surname>Kadoch</surname><given-names>IJ</given-names></name><name><surname>Hosny</surname><given-names>G</given-names></name><name><surname>Bagirova</surname><given-names>M</given-names></name><name><surname>Frydman</surname><given-names>R</given-names></name></person-group><article-title>Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation</article-title><source> Fertil Steril</source><year>2004</year><volume>81</volume><fpage>1554</fpage><lpage>1558</lpage><pub-id pub-id-type="pmid">15193476</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharara</surname><given-names>FI</given-names></name><name><surname>McClamrock</surname><given-names>HD</given-names></name></person-group><article-title>The effect of aging on ovarian volume measurements in infertile women</article-title><source> Obstet Gynecol</source><year>1999</year><volume>94</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10389718</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>C&#x000e9;drin-Durnerin</surname><given-names>I</given-names></name><name><surname>Bst&#x000e4;ndig</surname><given-names>B</given-names></name><name><surname>Parneix</surname><given-names>I</given-names></name><name><surname>Bied-Damon</surname><given-names>V</given-names></name><name><surname>Avril</surname><given-names>C</given-names></name><name><surname>Decanter</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of oral contraceptive, synthetic progestrogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort befor GNRH antagonist protocol</article-title><source> Hum Reprod</source><year>2007</year><volume>22</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">16936304</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obruca</surname><given-names>A</given-names></name><name><surname>Fischl</surname><given-names>FH</given-names></name><name><surname>Huber</surname><given-names>Jc</given-names></name><name><surname>Programming</surname><given-names>oocyte retrival using oral contraceptive pretreatment before ovarian stimulation with a GNRH antagonist (Cerotide) protocol</given-names></name></person-group><source>Hum Reprod </source><year>2001</year><volume>16</volume><fpage>89</fpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smulders</surname><given-names>B</given-names></name><name><surname>Van</surname><given-names>Oirschot SM</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name><name><surname>Rombauts</surname><given-names>L</given-names></name><name><surname>Kremer</surname><given-names>JA</given-names></name></person-group><article-title>Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</article-title><source> Cochrane Database Syst Rev</source><year>2010</year><volume>20</volume><fpage>CD006109</fpage><pub-id pub-id-type="pmid">20091585</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanchin</surname><given-names>R</given-names></name><name><surname>Salomon</surname><given-names>L</given-names></name><name><surname>Castelo-</surname><given-names>Branco A</given-names></name><name><surname>Olivennes</surname><given-names>F</given-names></name><name><surname>Frydman</surname><given-names>N</given-names></name><name><surname>Frydman</surname><given-names>R</given-names></name></person-group><article-title>Luteal estradiol pre-treatment coordinate follicular growth during controlled ovarian hyperstimulation with GNRH antagonist</article-title><source> Hum Reprod</source><year>2003</year><volume>18</volume><fpage>2698</fpage><lpage>2703</lpage><pub-id pub-id-type="pmid">14645194</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elassar</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>JS</given-names></name><name><surname>Engmann</surname><given-names>L</given-names></name><name><surname>Nulsen</surname><given-names>J</given-names></name><name><surname>Benadiva</surname><given-names>C</given-names></name></person-group><article-title>Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in-vitro fertilization in poor responders</article-title><source> Fertil Steril</source><year>2011</year><volume>95</volume><fpage>324</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">20797708</pub-id></element-citation></ref></ref-list></back></article>